OncoSec Medical Inc Stock Nasdaq
Equities
US68234L2079
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | - | Sales 2022 | - | Capitalization | 28.35M |
---|---|---|---|---|---|
Net income 2021 | -45M | Net income 2022 | -34M | EV / Sales 2021 | - |
Net cash position 2021 | 33.63M | Net cash position 2022 | 1.12M | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.59
x | P/E ratio 2022 |
-0.83
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 84.57% |
Managers | Title | Age | Since |
---|---|---|---|
David Canton
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Sandra Aung
PRN | Corporate Officer/Principal | - | 20-10-11 |
Bridget O'Keeffe
PRN | Corporate Officer/Principal | - | 21-02-17 |
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |